1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. - Garralda, E; Hoef, M van; Ochsenreither, S; Gianni, L; Lorusso, D; Fiedler, W; Keilholz, U; Klinghammer, K; Dicke, C; Kebenko, M (Annals of Oncology, 2018)